Monotreatment With Conventional Antirheumatic Drugs or Glucocorticoids in Rheumatoid Arthritis: A Network Meta-Analysis
Pooled result · Tender joint count reductionResult — go to the resultReduction 5.18 joints 95% CrI 4.07–6.28Authors' conclusion
This study's results support the present role of methotrexate as the primary reference conventional synthetic disease-modifying antirheumatic drug.
Study context
- Population
- Patients with RA in RCTs of mono-csDMARDs, GC, placebo or nonactive treatment (mean RA duration 79 months; mean disease activity score 6.3)
- Participants
- 13,260 patients132 RCTs
- Comparison
- Mono-csDMARDs or GC vs placebo or nonactive treatment, and vs MTX
- Outcome
- Tender joint count, absolute change adjusted for baseline disease activity
Methodological detailsrandom effect model, Cochrane RoB 2, PRISMA, protocol registered before data recording
- Random effect model
- Cochrane RoB 2
- PRISMA
- Protocol registered before data recording
Pooled result
Tender joint count reduction
Reduction
5.18 joints
95% CrI 4.07–6.28
As reported in the abstract
Further pooled results
| Outcome | Difference (joints) (95% CrI) | |
|---|---|---|
| Tender joint count vs MTXGCvs Oral MTXCrI | −2.54 (−5.16 to 0.08) | |
| Tender joint count vs MTXCyclophosphamidevs Oral MTXCrI | 6.08 (0.44–11.66) | |
| −10−5051015Difference, joints (linear scale) |
Tender joint count vs MTX
- Remaining drugs except cyclophosphamide associated with similar or lower tender joint counts vs MTX
Original publication
Monotreatment With Conventional Antirheumatic Drugs or Glucocorticoids in Rheumatoid Arthritis: A Network Meta-Analysis. JAMA Netw Open. Published 2 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →